A randomized proof-of-mechanism trial applying the ‘fast-fail’ approach to evaluating κ-opioid antagonism as a treatment for anhedonia

Journal: Nature Medicine

Published: 2020-03-30

DOI: 10.1038/s41591-020-0806-7

Affiliations: 18

Authors: 20

Go to article
Institutions Share
Duke Department of Psychiatry and Behavioral Sciences, United States of America (USA) 0.13
Duke Department of Radiology, United States of America (USA) 0.13
NIH National Institute of Mental Health (NIMH), United States of America (USA) 0.10
Yale Department of Psychiatry, United States of America (USA) 0.10
Department of Psychiatry, CWRU, United States of America (USA) 0.10
McLean Hospital, United States of America (USA) 0.08
Menninger Department of Psychiatry and Behavioral Sciences, BCM, United States of America (USA) 0.08
Duke Clinical Research Institute, United States of America (USA) 0.05
NYU Department of Psychiatry, United States of America (USA) 0.05
Department of Psychiatry, IUPUI, United States of America (USA) 0.03
The University of Sydney (USYD), Australia 0.03
Nash Family Department of Neuroscience, ISMMS, United States of America (USA) 0.03
Department of Psychiatry, ISMMS, United States of America (USA) 0.03
Michael E. DeBakey VA Medical Center (MEDVAMC), United States of America (USA) 0.03
School of Science, IUPUI, United States of America (USA) 0.02
Durham VA Medical Center (VAMC), United States of America (USA) 0.02
UCSF Department of Psychiatry and Behavioral Sciences, United States of America (USA) 0.02

Return

Except where otherwise noted © 2021 Springer Nature Limited. All Rights Reserved.
partner of AGORA, HINARI, OARE, INASP, ORCID, CrossRef and COUNTER